BC Week In Review | Jan 4, 2016
Clinical News

CPP-115: Phase Ib data

Top-line data from a 2-part, U.S. Phase Ib trial in healthy volunteers showed that CPP-115 for 14 days increased GABA levels by 150-200% from baseline in both the parietal-occipital cortex and the supplementary motor area...
BC Week In Review | Aug 17, 2015
Clinical News

Vigabatrin: Phase I/II data

Top-line data from an open-label, U.S. Phase I/II trial in 4 Tourrette’s disorder patients who were refractory to all other previous treatments showed that 1 patient receiving twice-daily oral vigabatrin for 8 weeks achieved a...
BC Week In Review | Sep 8, 2014
Clinical News

CPP-115: Phase I started

Catalyst began a 2-part, U.S. Phase Ib trial to evaluate single and multiple doses of CPP-115 in up to 38 healthy, male volunteers. The trial will evaluate increases in brain GABA levels, which Catalyst believes...
BC Week In Review | Apr 8, 2013
Company News

Catalyst Pharma neurology news

Catalyst disclosed in its 4Q12 earnings that it will require a strategic partner or grant funding for the "near-term advancement" of GABA transaminase inhibitor CPP-115 to treat West syndrome (infantile spasms). Last year, Catalyst reported...
BC Week In Review | Jun 4, 2012
Clinical News

CPP-115: Phase Ia data

A double-blind, placebo-controlled, U.S. Phase Ia trial in 55 healthy volunteers showed that single ascending-doses of 5-500 mg oral CPP-115 were well tolerated with no serious adverse events reported. Mean time to average peak blood...
BC Week In Review | Feb 20, 2012
Clinical News

CPP-115 regulatory update

Catalyst said the European Commission granted Orphan Drug designation for CPP-115 to treat West Syndrome (infantile spasms). The GABA transaminase inhibitor is in Phase I testing. CPP-115 has Orphan Drug designation in the U.S. for...
BC Week In Review | Jan 2, 2012
Clinical News

CPP-115: Phase Ia started

Catalyst began a double-blind, placebo-controlled, single ascending-dose U.S. Phase Ia trial to evaluate CPP-115 in about 48 healthy volunteers. Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Coral Gables, Fla.   Product: CPP-115   Business: Neurology   Molecular...
BC Week In Review | Jan 2, 2012
Clinical News

CPP-115 regulatory update

FDA granted Fast Track designation for Catalyst's CPP-115 to treat cocaine addiction. The GABA transaminase inhibitor is in Phase I testing for the indication. CPP-115 also has Orphan Drug designation in the U.S. to treat...
BC Innovations | Dec 15, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Addiction 4-Aminobutyrate aminotransferase (ABAT; GABA-AT) Rat studies identified a GABA-AT inactivator that could help treat cocaine addiction. In rats, oral treatment with the GABA-AT inactivator...
BC Week In Review | Dec 5, 2011
Clinical News

CPP-115: Phase Ia start

Catalyst disclosed in its 3Q11 earnings that this quarter it will begin a U.S. Phase Ia trial to evaluate CPP-115 in healthy volunteers. Details were not disclosed. Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Coral Gables, Fla....
Items per page:
1 - 10 of 15